Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study.

Int Neurourol J · 2022 · PMC9260321 · PMID 35793990

Europe PMC DOI

hedged sentences

0.0684

closest p · 1.4× alpha

0.0684

boldest claim

The sentences

a trend toward significanceP=0.0684so close (0.05 < p ≤ 0.1)

The ∆ episode of urgency/24 hours was significantly lower in the DA-8010 5 mg group at 4 weeks (P=0.0278) and 8 weeks (P=0.0092), while DA-8010 2.5 mg showed a trend toward significance at 8 weeks (P=0.0684).

also in 3,729 other papers

did not reach statistical significanceno p-value reported

For most of the other efficacy variables, numerically noticeable improvements in OAB symptoms were observed in both the DA-8010 2.5 mg and 5 mg groups compared with the placebo group, although the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.